Cue Biopharma (CUE) Operating Leases (2019 - 2025)

Cue Biopharma has disclosed Operating Leases across 7 years of filings, most recently posting $2.3 million for Q4 2025.

• Operating Leases for Q4 2025 came in at $2.3 million, up 127.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.3 million (up 127.92% YoY), and the FY2025 annual result was $2.3 million, up 127.92% from the prior year.
• Operating Leases came in at $2.3 million for Q4 2025 at Cue Biopharma, down from $2.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.8 million in Q2 2022 to a low of $176000.0 in Q1 2025.
• The 5-year median for Operating Leases is $2.9 million (2025), against an average of $3.0 million.
• Across the five-year window, Operating Leases soared 532.4% in 2023 and tumbled 93.18% in 2025, its largest moves.
• Cue Biopharma's Operating Leases stood at $5.1 million in 2021, then sank by 90.24% to $500000.0 in 2022, then jumped by 532.4% to $3.2 million in 2023, then slumped by 68.28% to $1.0 million in 2024, then surged by 127.92% to $2.3 million in 2025.
• The last three Operating Leases figures came in at $2.3 million (Q4 2025), $2.7 million (Q3 2025), and $3.1 million (Q2 2025), per Business Quant data.